The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia

  • Camillo Porta | c.porta@smatteo.pv.it Medical Oncology and Laboratory of Pre-clinical Oncology and Experimental Therapies IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
  • Federica Tagliani Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.

Abstract

Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Editorials
Statistics
  • Abstract views: 1006

  • FULL TEXT: 152
How to Cite
Porta, C., & Tagliani, F. (2011). The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia. Oncology Reviews, 2(2), 67-68. https://doi.org/10.4081/oncol.2008.111